Arvinas, Inc.

Arvinas Inc. is an innovative biopharmaceutical company focused on the development of protein degradation therapies. These therapies aim to address previously undruggable targets by leveraging the body's natural protein disposal systems to selectively degrade disease-causing proteins. Arvinas’ primary intent is to develop novel treatments for challenging diseases, including various forms of cancer and neurodegenerative disorders. Central to its operations is a proprietary technology platform known as PROTAC (Proteolysis Targeting Chimeras), which distinguishes it from traditional small-molecule inhibitors. The company’s initiatives are pushing the frontiers of medicine, with ongoing clinical trials testing the efficacy and safety of its pioneering approaches. Arvinas Inc. plays a crucial role in the biotechnology sector, driving forward new paradigms in targeted therapy and expanding the horizons of drug development. Founded in 2013, Arvinas is based in New Haven, Connecticut, contributing to the robust life sciences ecosystem in the region.